Rabe 2009.

Trial name or title	DAPS‐Dalteparin in Patients with Superficial Leg Vein Phlebitis in Addition to Compression Treatment ‐ a Placebo‐Controlled Phase III Study.
Methods	Randomised, double‐blind, multicentre, phase III trial.
Participants	276 participants with superficial leg vein phlebitis.
Interventions	Compression stockings (30 mmHg) for 3 months and either dalteparin 10,000 IU (group A) or placebo (group B) for 14 days.
Outcomes	Primary endpoint: progression of the thrombotic process during treatment period as confirmed by ultrasound. Sonographic assessment planned in all participants on days 1, 7, 14, and 90. Secondary endpoints: pain assessment by visual analogue scale and calculation of symptom scores (tension, heaviness, swelling).
Starting date	Not reported.
Contact information	Rabe E.
Notes